Polaris Genomics
Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools.
About Polaris Genomics
Polaris Genomics is mapping molecular biomarkers to chart a new course for objective mental health diagnostics and novel therapeutics. Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools. The company's genomics-based ADAPT Platform™ curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions ’ including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT). The ADAPT Platform™ comprises: 1. targeted neuropsychiatric gene panel, which contains 1000+ transcriptomic biomarkers related to known system pathways in neuropsychiatric conditions; 2. deep analytics (AI/ML) engine; and 3. expanding data lake and sample repository. ADAPT has identified transcriptomic biomarkers for PTSD, resulting in the first-of-its-kind clinical blood test for PTSD screening, Polaris' PTS-ID™.
Company Facts
- Headquarters
- Gaithersburg
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- seed
- Total Funding
- $5,550,000
- Last Funding Type
- debt_financing
- Last Funding Date
- 2025-08-26
- Website
- polarisgenomics.com
Industries & Categories
Bioinformatics, Biotechnology, Clinical Trials, Genetics, Health Care, Health Diagnostics, Life Science, Pharmaceutical, Therapeutics, Wellness
Social Links
Canonical: https://fsome.com/organization/polaris-genomics-18254 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.